Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

FDA approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

July 24, 2026

Vol.52 No.29

News Analysis

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).

June 26, 2026

Vol.52 No.25

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

Physicians and researchers at Winship Cancer Institute of Emory University announced they have administered the first investigational in vivo CAR-T cell therapy in the United States for relapsed and refractory multiple myeloma.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

FDA has granted Hyrnuo (sevabertinib) priority review status for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations in patients with no prior therapy.

May 22, 2026

Vol.52 No.20

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

YOU MAY BE INTERESTED IN

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

AI in action: MANAscore tool moves closer to clinic

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

YOU MAY BE INTERESTED IN

FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

AI in action: MANAscore tool moves closer to clinic

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.